Company intelligence / Profile preview

Xanagen

Kawasaki, Kanagawa, Japan

Ownership: Private
Development stage: Other

Overview

Xanagen is a Japanese biotechnology company specializing in bioinformatics and genomics services. Founded as a joint venture involving Kyowa Hakko Kogyo (now Kyowa Kirin), the company is best known for developing the "Genome Gambler" system, a comprehensive software suite used for automated and manual genome annotation. Xanagen provides specialized services in microbial genome sequencing, metagenomics, and the construction of genomic libraries for industrial and academic research. Its proprietary XanaGenome database and XanaMine analysis tools have been instrumental in the characterization of diverse organisms, including plant pathogens and extremophiles.

Industry: Biomedical IT and Biomedical Data Platforms

Partnerships

Kyowa Hakko KogyoNational Institute of Genetics (Japan)Japan Science and Technology Corporation (JST)

Beyond the preview

Go deeper on Xanagen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xanagen.

Explore the full profile